Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zheng M. Classification and pathology of lung cancer. Surg Oncol Clin N Am. 2016;25(3):447–468. doi:10.1016/j.soc.2016.02.003
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: checkMate 078 randomized Phase III Clinical Trial. J Thorac Oncol. 2019;14(5):867–875. doi:10.1016/j.jtho.2019.01.006
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937. doi:10.1016/S1470-2045(19)30167-6
   PubMed Web of Science ®Google Scholar
• Deng X, Xiong W, Jiang X, et al. LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. Cell Death Dis. 2020;11(11):945. doi:10.1038/s41419-020-03147-9
   PubMed Web of Science ®Google Scholar
• Yu WD, Wang H, He QF, Xu Y, Wang XC. Long noncoding RNAs in cancer-immunity cycle. J Cell Physiol. 2018;233(9):6518–6523. doi:10.1002/jcp.26568
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994–1004. doi:10.1038/s41591-018-0057-z
   PubMed Web of Science ®Google Scholar
• Li Y, Shen R, Wang A, et al. Construction of a prognostic immune-related LncRNA risk model for lung adenocarcinoma. Front Cell Dev Biol. 2021;9:648806. doi:10.3389/fcell.2021.648806
   PubMed Web of Science ®Google Scholar
• Jin D, Song Y, Chen Y, Zhang P. Identification of a seven-lncRNA immune risk signature and construction of a predictive nomogram for lung adenocarcinoma. Biomed Res Int. 2020;2020:7929132. doi:10.1155/2020/7929132
   PubMed Web of Science ®Google Scholar
• Mu L, Ding K, Tu R, Yang W. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma. J Transl Med. 2021;19(1):127. doi:10.1186/s12967-021-02800-x
   PubMed Web of Science ®Google Scholar
• Li JP, Li R, Liu X, et al. A seven immune-related lncRNAs model to increase the predicted value of lung adenocarcinoma. Front Oncol. 2020;10.
   Web of Science ®Google Scholar
• Wang J, Yin X, Zhang YQ, Ji X. Identification and validation of a novel immune-related four-lncRNA signature for lung adenocarcinoma. Front Genet. 2021;12:111.
   Web of Science ®Google Scholar
• Zhang B, Wang R, Li K, et al. An immune-related lncRNA expression profile to improve prognosis prediction for lung adenocarcinoma: from bioinformatics to clinical word. Front Oncol. 2021;11:671341. doi:10.3389/fonc.2021.671341
   PubMed Web of Science ®Google Scholar
• Miao H, Chen D, Li R, et al. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung. Biosci Rep. 2021;41(1):BSR20202444. doi:10.1042/BSR20202444
   PubMed Web of Science ®Google Scholar
• Lv Y, Lin SY, Hu FF, et al. Landscape of cancer diagnostic biomarkers from specifically expressed genes. Brief Bioinform. 2020;21(6):2175–2184. doi:10.1093/bib/bbz131
   PubMed Web of Science ®Google Scholar
• Hong W, Liang L, Gu Y, et al. Immune-related lncRNA to construct novel signature and predict the immune landscape of human hepatocellular carcinoma. Mol Ther Nucleic Acids. 2020;22:937–947. doi:10.1016/j.omtn.2020.10.002
   PubMedGoogle Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Finotello F, Mayer C, Plattner C, et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019;11(1):34. doi:10.1186/s13073-019-0638-6
   PubMed Web of Science ®Google Scholar
• Plattner C, Finotello F, Rieder D. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Methods Enzymol. 2020;636:261–285.
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017;6:e26476. doi:10.7554/eLife.26476
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Aran D. Cell-type enrichment analysis of bulk transcriptomes using xCell. Methods Mol Biol. 2020;2120:263–276.
   PubMedGoogle Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Villacampa G, Sveen A, et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann Oncol. 2019;30(10):1622–1629. doi:10.1093/annonc/mdz287
   PubMed Web of Science ®Google Scholar
• Tamminga M, Hiltermann TJN, Schuuring E, Timens W, Fehrmann RS, Groen HJ. Immune microenvironment composition in non-small cell lung cancer and its association with survival. Clin Transl Immunol. 2020;9(6):e1142. doi:10.1002/cti2.1142
   PubMed Web of Science ®Google Scholar
• Wan J, Guo C, Fang H, Xu Z, Hu Y, Luo Y. Autophagy-related long non-coding RNA is a prognostic indicator for bladder cancer. Front Oncol. 2021;11:647236. doi:10.3389/fonc.2021.647236
   PubMed Web of Science ®Google Scholar
• Zeng L, Lyu X, Yuan J, et al. Erratum: long non-coding RNA LINC01116 is overexpressed in lung adenocarcinoma and promotes tumor proliferation and metastasis. Am J Transl Res. 2021;13(4):3919–3920.
   PubMed Web of Science ®Google Scholar
• Wang J, Gao J, Chen Q, et al. LncRNA LINC01116 contributes to cisplatin resistance in lung adenocarcinoma. Onco Targets Ther. 2020;13:9333–9348. doi:10.2147/OTT.S244879
   PubMed Web of Science ®Google Scholar
• Shang B, Li Z, Li M, et al. Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway. Thorac Cancer. 2021;12(14):2093–2103. doi:10.1111/1759-7714.14042
   PubMed Web of Science ®Google Scholar
• Sakurai K, Reon BJ, Anaya J, Dutta A. The lncRNA DRAIC/PCAT29 locus constitutes a tumor-suppressive nexus. Mol Cancer Res. 2015;13(5):828–838. doi:10.1158/1541-7786.MCR-15-0016-T
   PubMed Web of Science ®Google Scholar
• Han K, Qian K, Zhao T, Liu XS, Zhang Y. Prediction of prognosis of patients with lung cancer in combination with the immune score. Biosci Rep. 2021;41(5). doi:10.1042/BSR20203431
   Web of Science ®Google Scholar